2020
The impact of insurance type on listing status and wait‐list mortality of patients with left ventricular assist devices as bridge to transplantation
Briasoulis A, Akintoye E, Inampudi C, Hammoud A, Alvarez P. The impact of insurance type on listing status and wait‐list mortality of patients with left ventricular assist devices as bridge to transplantation. ESC Heart Failure 2020, 7: 804-810. PMID: 32135039, PMCID: PMC7261523, DOI: 10.1002/ehf2.12655.Peer-Reviewed Original ResearchConceptsLeft ventricular assist deviceInsurance typeVentricular assist deviceTime of listingWaiting listAssist deviceHeart transplantation candidatesOrgan Sharing registryWait-list mortalityRisk regression analysisDifferent insurance typesAdequate health insurance coverageHealth insurance coverageStatus 1APublic health insuranceCumulative incidenceTransplantation candidatesTransplantation ratesUnited NetworkPost-HTMA patientsType of insurancePatientsMortalityCumulative mortality
2018
Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease
Briasoulis A, Inampudi C, Akintoye E, Alvarez P, Panaich S, Vaughan‐Sarrazin M. Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease. Journal Of The American Heart Association 2018, 7: e008773. PMID: 29622591, PMCID: PMC6015407, DOI: 10.1161/jaha.118.008773.Peer-Reviewed Original ResearchConceptsValvular heart diseaseAtrial fibrillationMedicare beneficiariesIschemic strokeHeart diseaseNew-onset atrial fibrillationNon-vitamin K anticoagulantsGastrointestinal bleeding ratesLarge community-based samplePropensity-matched sampleCommunity-based sampleMajor bleedingNongastrointestinal bleedingCause mortalitySystemic thromboembolismVersus WarfarinPrimary outcomePropensity matchingMyocardial infarctionBleeding rateLower riskPatientsRivaroxabanWarfarinDabigatran